Industry
Biotechnology
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Loading...
Open
1.53
Mkt cap
74M
Volume
522K
High
1.73
P/E Ratio
-1.35
52-wk high
1.79
Low
1.53
Div yield
N/A
52-wk low
0.51
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 4:38 pm
Portfolio Pulse from Avi Kapoor
October 29, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 11:34 am
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
October 25, 2024 | 10:05 am
Portfolio Pulse from Benzinga Insights
October 24, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:14 am
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 9:18 am
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 10:55 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.